Skip to main navigation Skip to search Skip to main content

Update on the use of biologics in vasculitides

  • SUNY Buffalo

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Vasculitides are disease in which injury to blood vessels leads to various degrees and types of organ dysfunction. They are subdivided into different groups dependent on the size of blood vessels involved as well as other particular clinical features. Therapy is dependent upon the size of the blood vessels involved and the nature of the disease. For medium and large vessel vasculitides, glucocorticoids, cyclophosphamide, azathioprine and methotrexate have been the mainstay for induction and maintenance of remission. Because of potential for side effects from standard therapies, various biologic agents have been evaluated in the treatment of ANCA positive vasculitis (AAV), cryoglobulinemic vasculitis, Behcet’s disease and Takayasu’s Arteritis (TAK). In this article, we present a review on biologic agents used in various vasculitides.

Original languageEnglish
Pages (from-to)558-562
Number of pages5
JournalCurrent Pharmaceutical Biotechnology
Volume15
Issue number6
DOIs
StatePublished - Sep 1 2014

Keywords

  • Behcet’s disease
  • Biologics
  • Takayasu arteritis
  • Vasculitis.granulomatous polyangiitis

Fingerprint

Dive into the research topics of 'Update on the use of biologics in vasculitides'. Together they form a unique fingerprint.

Cite this